Impact of mycophenolate mofetil dose reduction on allograft outcomes in kidney transplant recipients on tacrolimus-based regimens: A systematic review

Annals of Pharmacotherapy

Volumn 45, Issue 2, 2011, Pages 248-257

  Su, Victoria C H ^a   Greanya, Erica D ^a,b   Ensom, Mary H H ^c,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c Faculty of Pharmaceutical Sciences   (Canada)

^d CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Allograft outcomes; Kidney transplant; Mycophenolate; Systematic review; Tacrolimus

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; INTERLEUKIN 2; INTERLEUKIN 3; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLATE MOFETIL;

ACUTE GRAFT REJECTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLASSIFICATION; COCHRANE LIBRARY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBASE; ENTERIC COATED TABLET; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MEDLINE; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; ALLOGRAFT; ANALOGS AND DERIVATIVES; DRUG COMBINATION; GRAFT REJECTION;

ALLOGRAFTS; CYCLOSPORINE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; TACROLIMUS;

EID: 79951920312     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P456     Document Type: Article

References (45)

1. Hardinger KL, Koch MJ, Brennan DC. Current and future immunosuppressive strategies in renal transplantation. Pharmacotherapy 2004;24:1159-76. (Pubitemid 39128840)
2. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995;345:1321-5.
3. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996;61:1029-37.
4. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995;60:225-32.
5. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997;63:39-47. (Pubitemid 27036687)
6. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000;69:2405-9. (Pubitemid 30409012)
7. Gaston RS, Kaplan B, Shah T, et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant 2009;9:1607-19.
8. Le Meur Y, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007;7:2496-503. (Pubitemid 47566324)
9. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008;86:1043-51.
10. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-29. (Pubitemid 39665325)
11. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006;6:1111-31.
12. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 1999;318:1104-7. (Pubitemid 29192148)
13. Shapiro R, Jordan M, Scantlebury V, et al. FK 506 in clinical kidney transplantation. Transplant Proc 1991;23:3065-7.
14. Mayer AD. Chronic rejection and graft half-life: five-year follow-up of the European Tacrolimus Multicenter Renal Study. Transplant Proc 2002;34:1491-2.
15. Gonwa T, Johnson C, Ahsan N, et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003;75:2048-53. (Pubitemid 36793291)
16. Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003;14:2381-6. (Pubitemid 37052386)
17. Pascual J, Ocana J, Marcen R, et al. Mycophenolate mofetil tolerability and dose changes in tacrolimus-treated renal allograft recipients. Transplant Proc 2006;38:2398-9. (Pubitemid 44693687)
18. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003;17:200-5. (Pubitemid 36748465)
19. Tierce JC, Porterfield-Baxa J, Petrilla AA, Kilburg A, Ferguson RM. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transplant 2005;19:779-84. (Pubitemid 41748732)
20. Pietruck F, Budde K, Salvadori M, et al. Efficacy and safety of entericcoated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials. Clin Transplant 2007;21:117-25. (Pubitemid 46189596)
21. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004;4:231-6. (Pubitemid 38248526)
22. de Jonge H, Naesens M, Kuypers DR. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit 2009;31:416-35.
23. U.S. Preventive Services Task Force. Guide to clinical preventive services: report of the U.S. Preventive Services Task Force. 2nd ed. Baltimore: Williams & Wilkins, 1996:861-2.
24. Walker R, Thomas M, Goodman D, Campbell S, Chadban S. Combination therapy with tacrolimus and mycophenolate mofetil: effects of early and late minimization of mycophenolate mofetil after renal transplant. Clin Transplant 2008;22:594-602.
25. Badowski M, Gurk-Turner C, Cangro C, et al. The impact of reduced immunosuppression on graft outcomes in elderly renal transplant recipients. Clin Transplant 2009;23:930-7.
26. Pascual J, van Hooff JP, Salmela K, Lang P, Rigotti P, Budde K. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. Transplantation 2006;82:55-61. (Pubitemid 44296978)
27. Vanrenterghem Y, van Hooff JP, Squifflet JP, et al. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transplant 2005;5:87-95. (Pubitemid 40095131)
28. Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006;82:102-7. (Pubitemid 44296984)
29. Hardinger KL, Brennan DC, Lowell J, Schnitzler MA. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 2004;17:609-16. (Pubitemid 40104663)
30. Machnicki G, Ricci JF, Brennan DC, Schnitzler MA. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients. Pharmacoeconomics 2008;26:951-67.
31. Opelz G, Dohler B. Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation 2008;86:371-6.
32. Takemoto SK, Pinsky BW, Schnitzler MA, et al. A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients. Am J Transplant 2007;7:2704-11. (Pubitemid 350045761)
33. Kahu J, Kyllonen L, Salmela K. Impact of mycophenolate mofetil intolerance on early results of kidney transplantation. Transplant Proc 2005;37:3276-9. (Pubitemid 41659863)
34. Zhu QG, Zhao YK, Liu W, Luo H, Qiu Y, Gao ZZ. Two-year observation of a randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplantation. Chin Med Sci J 2008;23:244-8.
35. Khosroshahi HT, Nahali A, Gojazadeh M, Shoja MM. Comparison of transplanted kidney function in patients on two different doses of mycophenolate mofetil. Transplant Proc 2006;38:2035-7. (Pubitemid 46068486)
36. Kaushik M, Kay MD, Bagul A, Nicholson ML. Morbidity rates with reduced mycophenolate mofetil dosage: a single-center experience. Transplant Proc 2006;38:2864-5. (Pubitemid 44737968)
37. Squifflet JP, Backman L, Claesson K, et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 2001;72:63-9. (Pubitemid 32652507)
38. Miller J, Mendez R, Pirsch JD, Jensik SC. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000;69:875-80. (Pubitemid 30174114)
39. Lam S, Partovi N, Ting LSL, Ensom MHH. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction? Ann Pharmacother 2008;42:1037-47. DOI 10.1345/aph.1K628
40. Ciancio G, Burke GW, Gaynor JJ, et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. Transplantation 2008;86:67-74.
41. Cooper M, Deering KL, Slakey DP, et al. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients. Transplantation 2009;88:514-20.
42. Sollinger HW, Sundberg AK, Leverson G, Voss BJ, Pirsch JD. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients. Transplantation 2010;89:446-51.
43. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 2008;85:1675-85.
44. Zafrani L, Truffaut L, Kreis H, et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. Am J Transplant 2009;9:1816-25.
45. Health Canada Drug Product Database. Hoffman-La Roche Ltd. Cell-Cept Monograph. http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code = 19525 (accessed 2010 Mar 30).